Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An OBServational Prospective Study in France: Adherence to APAlutamide in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients in France

NCT07451002 is registered in ClinicalTrials.gov with Janssen Cilag S.A.S. as lead sponsor.

NCT NCT07451002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07451002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An OBServational Prospective Study in France: Adherence to APAlutamide in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients in France
Lead sponsor
Janssen Cilag S.A.S.
Phase
Observational
Overall status
Recruiting
Start date
December 18, 2025
Completion date
September 18, 2028
Enrollment
540 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone-sensitive prostate cancer, prostatic neoplasms